Intel (NASDAQ: INTC), down 10%;
Boeing (NYSE: BA), down 8%; and
Amgen (NASDAQ: AMGN), off by 4%. For perspective, last month the Dow Jones Industrial Average overall gained a little less than 3%.
That trio is a curious mix. Usually, there’s at least a semi-clear common thread among the big names logging the worst losses. But, there aren’t many similarities between a chipmaker, an aircraft manufacturer, and a pharmaceutical outfit.
There is one common element among these Dow laggards, however: Their recent share price weakness is attributable to disappointing quarterly reports that portend trouble ahead.
Intel’s first-quarter numbers weren’t terrible. Revenue fell 1% year over year, and operating profits slumped by 6%. Given the challenging, turbulent environment created by the pandemic, however and the fact that earnings of $1.39 per share soundly trounced estimates of $1.15 those results could be considered a victory.
Senior Vice President of Investor Relations
Good evening. Welcome to the Vertex First Quarter 2021 Financial Results Conference Call. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Making prepared remarks on the call tonight, we have Dr. Reshma Kewalramani, Vertex s CEO and President; Stuart Arbuckle, Chief Commercial and Operations Officer and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast slides on our website as you listen to this call. This conference call is being recorded and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today s press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation those regarding Vertex s marketed CF medicines, our pipeline, expectations regarding the closing of the CRISPR transaction, which is subje
One of the shining jewels of UC San Francisco’s research program has received a $25 million gift that will ensure the success of its daring mission for many years to come. The newly named Sandler Program for Breakthrough Biomedical Research – previously known as the Program in Breakthrough Biomedical Research (PBBR) – has for 23 years supported the boldest, least explored research ideas in the life sciences.
The program, the brainchild of Nobel laureate and former UCSF Chancellor J. Michael Bishop, MD, is unconventional in its audacity, simplicity, and speed: PBBR applicants are asked to describe their most adventurous idea for a research project, in two pages or less, and in return they receive a funding decision within 30 days.